Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

[1]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[2]  B. Howie,et al.  Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer , 2017, Science.

[3]  J. Gartner,et al.  Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer , 2017, Clinical Cancer Research.

[4]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[5]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[6]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[7]  Jared Gartner,et al.  Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor , 2016, Cancer Immunology Research.

[8]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[9]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[11]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[12]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[13]  S. Rosenberg,et al.  Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. , 2013, Blood.

[14]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[15]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[16]  C. Cohen,et al.  Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity , 2012, The Journal of Immunology.

[17]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[18]  Marianna Sabatino,et al.  Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.

[19]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kristine Broglio,et al.  Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Yangbing Zhao,et al.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. , 2006, Cancer research.

[22]  J. Aldrich.  R.A. Fisher and the making of maximum likelihood 1912-1922 , 1997 .